The goal of the CFTR Chemical Compound program is to enable cystic fibrosis research scientists to test known cystic fibrosis transmembrane conductance regulator (CFTR) modulating compounds in different functional assays.
Site Search
Roche has acquired a set of potentiator compounds from Enterprise Therapeutics and intends to study them for the treatment of CF. The Cystic Fibrosis Foundation previously provided funding to Enterprise to develop these potential medicines.
Influenza, or “the flu,” is a highly contagious respiratory illness that is caused by a virus. For people with cystic fibrosis, getting the flu may cause a worsening of symptoms and lead to a faster decline in lung function.
The faulty gene that causes cystic fibrosis disrupts the normal flow of salt and water in and out of the lungs and other organs. This salt imbalance results in thick, sticky mucus that builds up in the lungs, allowing germs to thrive and multiply.
Dr. Frank Accurso, director of cystic fibrosis clinical research at Children's Hospital Colorado and University of Colorado Denver, participated in a congressional roundtable discussion at National Jewish Health in Denver, Colorado.
Every person has two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. A person must inherit two copies of the CFTR gene that contain mutations — one copy from each parent — to have cystic fibrosis.
In an international research project, scientists are examining cystic fibrosis transmembrane conductance regulator (CFTR) mutations to determine which ones cause CF and to provide additional information associated with these mutations. Their findings are available in an online searchable database.
There are many things you can do to help reduce the risk of getting or spreading germs while traveling.
A former clinical nurse explains why you should get your flu shot.